Eledon Pharmaceuticals (ELDN) PE Ratio: History & Chart

Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/E ratio is N/A as of 2026-10-06T15:41:43.900Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:41:43.900Z.

Quote observation: 2026-10-06T15:40:24.000Z. Amounts in USD. The price header may show a later quote.

Quote price: 2.505
Unrounded diluted TTM EPS · period ending 2026-06-30: -0.99

FMP input reference: d443e069440aa0ac5a32f25afa0d38c48efe58a411ec60778b8439bb1c5cf92a

Forward PE Ratio|PEG Ratio|P/B Ratio|EPS|All Metrics

ELDN PE Ratio Metrics

PE RATIO

N/A

ELDN Competitors' PE Ratio

ELDN

Eledon Pharmaceuticals, Inc.

Current

Market Cap

$193.36M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ANTX

AN2 Therapeutics, Inc.

vs ELDN

Market Cap

$189.63M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CNTN

Canton Strategic Holdings Inc

vs ELDN

Market Cap

$187.79M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ETRA

Electra Therapeutics Inc.

vs ELDN

Market Cap

$203.96M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ORMP

Oramed Pharmaceuticals Inc.

vs ELDN

Market Cap

$182.33M

PE Ratio

1.08

TTM Avg

2.35

3Y Avg

8.36

5Y Avg

8.36

DERM

Journey Medical Corporation

vs ELDN

Market Cap

$179.82M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CMPX

Compass Therapeutics, Inc.

vs ELDN

Market Cap

$178.97M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PDEX

Pro-Dex, Inc.

vs ELDN

Market Cap

$208.90M

PE Ratio

15.88

TTM Avg

14.32

3Y Avg

17.96

5Y Avg

17.40

CUE

Cue Biopharma, Inc.

vs ELDN

Market Cap

$175.18M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DTIL

Precision BioSciences, Inc.

vs ELDN

Market Cap

$174.99M

PE Ratio

N/A

TTM Avg

11.57

3Y Avg

11.57

5Y Avg

11.57

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Eledon Pharmaceuticals, Inc. (ELDN)	$193.36M	N/A	N/A	N/A	N/A
AN2 Therapeutics, Inc. (ANTX)vs ›	$189.63M	N/A	N/A	N/A	N/A
Canton Strategic Holdings Inc (CNTN)vs ›	$187.79M	N/A	N/A	N/A	N/A
Electra Therapeutics Inc. (ETRA)vs ›	$203.96M	N/A	N/A	N/A	N/A
Oramed Pharmaceuticals Inc. (ORMP)vs ›	$182.33M	1.08	2.35	8.36	8.36
Journey Medical Corporation (DERM)vs ›	$179.82M	N/A	N/A	N/A	N/A
Compass Therapeutics, Inc. (CMPX)vs ›	$178.97M	N/A	N/A	N/A	N/A
Pro-Dex, Inc. (PDEX)vs ›	$208.90M	15.88	14.32	17.96	17.40
Cue Biopharma, Inc. (CUE)vs ›	$175.18M	N/A	N/A	N/A	N/A
Precision BioSciences, Inc. (DTIL)vs ›	$174.99M	N/A	11.57	11.57	11.57

P/E Comparison

Trailing P/E

N/A

Forward P/E

N/A

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$2.50

÷

Forward EPS (Est.)

$-0.95

=

Forward P/E

N/A

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

See the Lowest P/E Ratio Stocks ranking →

PE Ratio: N/A

ELDN PE Ratio Metrics

ELDN Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics